크론병에 동반된 속발성 아밀로이드증에서 infliximab 치료
Secondary amyloidosis complication of Crohn disease treated with infliximab
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Secondary systemic (AA) amyloidosis is a severe complication of progressed Crohn disease (CD) characterized by the deposition of amyloid A in body organs and tissues. Various therapeutic approaches have been recommended, however there is still no effective treatment. Recently, several case reports have demonstrated the effects of anti-tumor necrosis factor-α therapy in patients with AA amyloidosis associated with CD. We report on a 35-year-old female patient with CD complicated by AA amyloidosis in the gastrointestinal tract and renal involvement, who was treated with infliximab. The infliximab therapy improved the gastrointestinal symptoms and decreased the serum creatinine.
Abstract
Secondary systemic (AA) amyloidosis is a severe complication of progressed Crohn disease (CD) characterized by the deposition of amyloid A in body organs and tissues. Various therapeutic approaches have been recommended, however there is still no effective treatment. Recently, several case reports have demonstrated the effects of anti-tumor necrosis factor-α therapy in patients with AA amyloidosis associated with CD. We report on a 35-year-old female patient with CD complicated by AA amyloidosis in the gastrointestinal tract and renal involvement, who was treated with infliximab. The infliximab therapy improved the gastrointestinal symptoms and decreased the serum creatinine.
참고문헌 (11)
- Obici L, "AA amyloidosis: basic knowledge, unmet needs and future treatments", Swiss Med Wkly, 142, pp.w13580~ (2012)
- Greenstein AJ, "Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients", Medicine (Baltimore), 71, pp.261~270 (1992)
- Wester AL, "Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998", Inflamm Bowel Dis, 7, pp.295~300 (2001)
- Iizuka M, "Infliximab as a treatment for systemic amyloidosis associated with Crohn’s disease", Gut, 55, pp.744~745 (2006)
- Iizuka M, "Efficacy of scheduled infliximab maintenance therapy on systemic amyloidosis associated with Crohn’s disease", Inflamm Bowel Dis, 17, pp.E67~E68 (2011)
- Cabezuelo JB, "Infliximab in the treatment of amyloidosis secondary to Crohn’s disease", Nefrologia, 32, pp.385~388 (2012)
- Boscá MM, "Secondary amyloidosis in Crohn’s disease:treatment with tumour necrosis factor inhibitor", Gut, 55, pp.294~295 (2006)
- Park YK, "Systemic amyloidosis with Crohn’s disease treated with infliximab", Inflamm Bowel Dis, 14, pp.431~432 (2008)
- Serra I, "Systemic amyloidosis in inflammatory bowel disease:retrospective study on its prevalence, clinical presentation, and outcome", J Crohns Colitis, 4, pp.269~274 (2010)
- Dember LM, "Eprodisate for the treatment of renal disease in AA amyloidosis", N Engl J Med, 356, pp.2349~2360 (2007)
- Ueda M, "FK506 inhibits murine AA amyloidosis: possible involvement of T cells in amyloidogenesis", J Rheumatol, 33, pp.2260~2270 (2006)